Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine
Background: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. Adolescents are at particular risk from meningococcal disease, therefore they might benefit from a booster dose of vaccine. The duration of ser...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1826256618059202560 |
|---|---|
| author | De Whalley, P Snape, MD Kelly, D Banner, C Lewis, S Diggle, L John, T Yu, L Omar, O Borkowski, A Pollard, A |
| author_facet | De Whalley, P Snape, MD Kelly, D Banner, C Lewis, S Diggle, L John, T Yu, L Omar, O Borkowski, A Pollard, A |
| author_sort | De Whalley, P |
| collection | OXFORD |
| description | Background: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. Adolescents are at particular risk from meningococcal disease, therefore they might benefit from a booster dose of vaccine. The duration of serologic response to such a booster in adolescents is unknown. Methods: In a previous study, English schoolchildren, aged 9 to 12 years, who had received a monovalent MenC glycoconjugate vaccine in 1999-2000, were given either a plain polysaccharide vaccine (MenC-PS group, n = 150) or a glycoconjugate vaccine (MenC-CRM group, n = 95) at 13 to 15 years of age. In this follow-up study, serum bactericidal antibody titers and specific immunoglobulin G concentrations were assessed 1 year later. Results were compared with unboosted controls of similar age (control group, n = 298). Results: Compliance with study protocol was achieved for 146 of the MenC-PS group, 92 of the MenC-CRM group, and 293 of the control group. Compared with the control group, both the MenC-PS and MenC-CRM groups had a significantly higher (P < 0.0001) geometric mean serum bactericidal antibody titers 1 year after the booster dose (geometric mean titers for MenC-PS group 3388 [95% confidence interval {CI}: 2460-4665]; MenC-CRM group 4417 [95% CI: 2951-6609]; control group 316 [95% CI: 252-396]). Specific immunoglobulin G concentration also rose and remained elevated 1 year after the booster. Conclusions: A booster dose of MenC vaccine given to adolescents produced a marked rise in bactericidal antibody, which remained elevated 1 year later. Introduction of an adolescent booster of MenC vaccine might provide enhanced long-term population control of the disease. © 2011 by Lippincott Williams and Wilkins. |
| first_indexed | 2024-03-06T18:05:05Z |
| format | Journal article |
| id | oxford-uuid:012be650-b58b-4101-9f03-cfd2d249225f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:05:05Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:012be650-b58b-4101-9f03-cfd2d249225f2022-03-26T08:33:26ZPersistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccineJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:012be650-b58b-4101-9f03-cfd2d249225fEnglishSymplectic Elements at Oxford2011De Whalley, PSnape, MDKelly, DBanner, CLewis, SDiggle, LJohn, TYu, LOmar, OBorkowski, APollard, ABackground: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. Adolescents are at particular risk from meningococcal disease, therefore they might benefit from a booster dose of vaccine. The duration of serologic response to such a booster in adolescents is unknown. Methods: In a previous study, English schoolchildren, aged 9 to 12 years, who had received a monovalent MenC glycoconjugate vaccine in 1999-2000, were given either a plain polysaccharide vaccine (MenC-PS group, n = 150) or a glycoconjugate vaccine (MenC-CRM group, n = 95) at 13 to 15 years of age. In this follow-up study, serum bactericidal antibody titers and specific immunoglobulin G concentrations were assessed 1 year later. Results were compared with unboosted controls of similar age (control group, n = 298). Results: Compliance with study protocol was achieved for 146 of the MenC-PS group, 92 of the MenC-CRM group, and 293 of the control group. Compared with the control group, both the MenC-PS and MenC-CRM groups had a significantly higher (P < 0.0001) geometric mean serum bactericidal antibody titers 1 year after the booster dose (geometric mean titers for MenC-PS group 3388 [95% confidence interval {CI}: 2460-4665]; MenC-CRM group 4417 [95% CI: 2951-6609]; control group 316 [95% CI: 252-396]). Specific immunoglobulin G concentration also rose and remained elevated 1 year after the booster. Conclusions: A booster dose of MenC vaccine given to adolescents produced a marked rise in bactericidal antibody, which remained elevated 1 year later. Introduction of an adolescent booster of MenC vaccine might provide enhanced long-term population control of the disease. © 2011 by Lippincott Williams and Wilkins. |
| spellingShingle | De Whalley, P Snape, MD Kelly, D Banner, C Lewis, S Diggle, L John, T Yu, L Omar, O Borkowski, A Pollard, A Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine |
| title | Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine |
| title_full | Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine |
| title_fullStr | Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine |
| title_full_unstemmed | Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine |
| title_short | Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine |
| title_sort | persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup c neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine |
| work_keys_str_mv | AT dewhalleyp persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine AT snapemd persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine AT kellyd persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine AT bannerc persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine AT lewiss persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine AT digglel persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine AT johnt persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine AT yul persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine AT omaro persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine AT borkowskia persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine AT pollarda persistenceofserumbactericidalantibodyoneyearafteraboosterdoseofeitheraglycoconjugateoraplainpolysaccharidevaccineagainstserogroupcneisseriameningitidisgiventoadolescentspreviouslyimmunizedwithaglycoconjugatevaccine |